EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks

Luana Layse Câmara de Almeida iD, Sayoane Pessoa Fernandes iD, Genil Dantas de Oliveira iD, Marcelly da Silveira Silva iD, Thalisson Amorim de Souza iD, Valnês S Rodrigues-Junior iD, Samuel Paulo Cibulski

Natural Products and Bioprospecting · 2025-12 · 15 (1)

DOI: 10.1007/s13659-025-00533-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Natural Products and Bioprospecting, online erschienen am 11.08.2025. Verfasst von Luana Layse Câmara de Almeida und 6 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Universidade Estadual da Paraíba (UEPB), Campina Grande, Paraíba, Braz…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 255 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Apoio à Pesquisa do Estado da Paraíba, National Council for Scientific and Technological Development, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) is a leading infectious disease killer and one of the major causes of deaths worldwide. Although TB is a curable and preventable disease, in 2023, approximately 10.8 million people fell ill with TB and there were an estimated 1.25 million of deaths worldwide. Despite some research progress for new drug candidates, drug repurposing, and new regimens, there is still an urgent need for the new medicins to treat TB, especially due to the growing cases of multidrug and extensively drug-resistant (MDR/XDR) strains. Drug resistance is a challenging obstacle to TB care and prevention globally, making TB harder and longer to treat, often with poorer outcomes for patients. The Actinomycetota encompass Gram-positive bacteria that produce a milieu of bioactive metabolites, including antibiotics, antiproliferative drugs, immunosuppressive agents, and other important medical molecules. Actinomycetota have a special place in the therapeutic arsenal to fight TB, as rifamycins, aminoglycosides, and cycloserine are derived from Streptomyces species, one of the most important genera in this phylum. Furthermore, hundreds of antimycobacterial metabolites have been isolated from Actinomycetota and can serve as effective drugs or useful agents for the discovery of new lead compounds to combat TB. The present review covers more than 171 isolated substances as potential antimycobacterial agents discovered between the years 1972 to 2024. Among the most potent compounds, with MIC in the submicromolar range, steffimycins, ilamycins/rufomycins, nosiheptide, actinomycins, lassomycin and boromycin are the most promising compounds. These compounds represent highly promising candidates for development of new antitubercular drugs. Additionally, some of these substances also demonstrated activity against resistant Mycobacterium tuberculosis (Mtb) strains, which is particularly relevant given the difficulty of treating MDR and XDR strains. Thus, actinobacteria have played and continue to play an important role in fight TB, remaining a promising source of antibiotic metabolites. Their unique metabolic diversity enables the production of metabolites with innovative mechanisms of action, making them a strategic reservoir for discovering therapies against untreatable forms of the disease. Graphical Abstract

Schlagwörter

Stichwörter der Autor:innen

ActinomyceteAntibioticsAntimycobacterial activityNatural productsSecondary metabolites

Autor:innen und Institutionen

  • Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Universidade Estadual da Paraíba (UEPB), Campina Grande, Paraíba, Brazil.
  • Laboratório Multiusuário de Caracterização e Análise (LMCA), Instituto de Pesquisa em Fármacos e Medicamentos, Universidade Federal da Paraíba (UFPB), João Pessoa Paraíba, Brazil.
  • Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Universidade Federal da Paraíba (UFPB), João Pessoa, Paraíba, Brazil.
  • Programa de Pós-Graduação em Ciências Farmacêuticas, Departamento de Farmácia, Universidade Estadual da Paraíba (UEPB), Campina Grande, Paraíba, Brazil. samuel.cibulski@ufrn.br.
  • FACISA-Faculdade de Ciências da Saúde do Trairi, Universidade Federal do Rio Grande do Norte (UFRN), Santa Cruz, Rio Grande do Norte, Brazil. samuel.cibulski@ufrn.br.

ORCID-Profile: Luana Layse Câmara de Almeida, Sayoane Pessoa Fernandes, Genil Dantas de Oliveira, Marcelly da Silveira Silva, Thalisson Amorim de Souza, Valnês S Rodrigues-Junior

Förderung

  • Fundação de Apoio à Pesquisa do Estado da Paraíba
  • National Council for Scientific and Technological Development
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

de Almeida, L. L. C., Fernandes, S. P., de Oliveira, G. D., da Silveira Silva, M., de Souza, T. A., Rodrigues-Junior, V. S., & Cibulski, S. P. (2025). Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks. Natural Products and Bioprospecting, 15(1). https://doi.org/10.1007/s13659-025-00533-8

Vancouver

de Almeida LLC, Fernandes SP, de Oliveira GD, da Silveira Silva M, de Souza TA, Rodrigues-Junior VS, et al. Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks. Natural Products and Bioprospecting. 2025;15(1). doi:10.1007/s13659-025-00533-8

BibTeX
@article{deAlmeida2025,
  author = {de Almeida, Luana Layse Câmara and Fernandes, Sayoane Pessoa and de Oliveira, Genil Dantas and da Silveira Silva, Marcelly and de Souza, Thalisson Amorim and Rodrigues-Junior, Valnês S and Cibulski, Samuel Paulo},
  title = {Harnessing Actinobacteria secondary metabolites for tuberculosis drug discovery: Historical trends, current status and future outlooks},
  journal = {Natural Products and Bioprospecting},
  year = {2025},
  volume = {15},
  number = {1},
  doi = {10.1007/s13659-025-00533-8}
}
Kostenlos starten →